Company Profile

LUPIN LTD.

NSE : LUPINBSE : 500257ISIN CODE : INE326A01037Industry : Pharmaceuticals & DrugsHouse : Lupin
BSE729.40-4.95 (-0.67 % )
PREV CLOSE (Rs.) 734.35
OPEN PRICE (Rs.) 733.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 55842
TODAY'S LOW / HIGH (Rs.)722.35 734.00
52 WK LOW / HIGH (Rs.)697.3 986
NSE729.30 -5 (-0.68 % )
PREV CLOSE(Rs.) 734.30
OPEN PRICE (Rs.) 734.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 729.30 (434 )
VOLUME 1076059
TODAY'S LOW / HIGH(Rs.) 722.25 734.60
52 WK LOW / HIGH (Rs.)697.2 986.1

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.69
TTM EPS (Rs.) 34.36
P/E Ratio 21.23
Book Value (Rs.) 383.22
Face Value (Rs.) 2
MCap (Rs. in Mn) 330129.07
Price/Earning (TTM) 16.45
Price/Sales (TTM) 2.90
Price/Book (MRQ) 1.90
PAT Margin (%) 12.71
ROCE (%) 14.44
Incorporation Year : 1983

Management Info :

Manju D Gupta - Chairman Nilesh Deshbandhu Gupta - Managing Director

Registered Office :

Address : Kalpataru Inspire, 3rd Floor,Off. Western Express Highway,Santacruz (East),
Mumbai,
Maharashtra-400055

Phone : 022 6640 2323

Website : www.lupinworld.com

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
16Aug08-16-2019$Lupin receives USFDA's approval for Hydrocortisone Valerate Cream Lupin receives USFDA's appro

Lupin has received approval for its Hydrocortisone Valerate Cream USP, 0.2% from the United States Food and Drug Administration (USFDA). Hydrocortisone Valerate Cream USP, 0.2% had an annual sales of approximately $15 million in the US (IQVIA MAT March 2019).

The company’s Hydrocortisone Valerate Cream USP, 0.2%, is the generic version of Westcort Cream, 0.2%, of Sun Pharmaceutical Industries, Inc. It is indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin has received approval for its Hydrocortisone Valerate Cre..
09Aug08-09-2019$Tech Mahindra, Hitech Corporation and Wipro to see some action today Tech Mahindra, Hitech Corpor

Tech Mahindra and BlockApps, the leading enterprise blockchain platform provider, have entered into partnership to accelerate the adoption of blockchain business networks. BlockApps will be leveraging Tech Mahindra’s extensive experience helping companies with digital transformation and the companies will be sharing resources to assist clients with integrating the BlockApps STRATO blockchain platform product and ensure a seamless experience.

Hitech Corporation has successfully completed construction work at Vizag for setting up of facility for manufacturing rigid plastic containers and has now commenced commercial production at the said plant with effect from August 08, 2019. The total capacity of the plant would be 3,000 MT and the same is being implemented in a phased manner.

Wipro has partnered with Camunda to Offer Workflow Automation Platform. This program will enable the company to integrate Camunda's products and Enterprise Platform with its offerings, and help customers who need workflow automation, but may not have the IT resources to build it themselves.

Adani Enterprises has reported net profit of Rs 468.79 crore for the quarter ended June 30, 2019 against net loss of Rs 7.16 crore for the same quarter in the previous year. Total income of the company increased by 99.48% at Rs 5,513.00 crore for Q1FY20 as compared Rs 2,763.70 crore for the corresponding quarter previous year.

Chromatic India has sold its factory located at Plot No W-34, MIDC, Phase-11, Dombivli Industrial Area, Dist. Thane containing by admeasurements 1000 M2 AREA with Open Industrial Cement roof shed of 117.60 M2 Area there on to Unilab Chemicals and Pharmaceuticals for total consideration of Rs 1.95 crore.

Tata Power Delhi Distribution (TPDDL), a joint venture between Tata Power and the Government of NCT of Delhi, has entered into an agreement with Council on Energy, Environment and Water (CEEW) for conducting research on integration of decentralised renewable energy into Delhi’s power grid.

United States Food and Drug Administration (USFDA) has completed inspection carried out at Lupin’s Nagpur oral solid manufacturing facility. The inspection was carried out between August 5, 2019 and August 8, 2019. The inspection for the oral solid facility at Nagpur closed without any 483 observations.

Tech Mahindra and BlockApps, the leading enterprise blockchain..
08Aug08-08-2019$Lupin reports 49% rise in Q1 consolidated net profit Lupin reports 49% rise in Q1

Lupin has reported results for first quarter ended June 30, 2019.

The company has reported a marginal rise of 3.83% in its net profit at Rs 445.93 crore for the quarter under review as compared to Rs 429.48 crore for the same quarter in the previous year. Total income of the company increased by 8.96% at Rs 2,998.07 crore for Q1FY20 as compared Rs 2,751.64 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a rise of 49.46% in its net profit at Rs 303.05 crore for the quarter under review as compared to Rs 202.76 crore for the same quarter in the previous year. Total income of the company increased by 11.15% at Rs 4,490.59 crore for Q1FY20 as compared Rs 4,040.13 crore for the corresponding quarter previous year.


Lupin has reported results for first quarter ended June 30, 201..
08Aug08-08-2019$USFDA completes inspection of Lupin’s Nagpur facility USFDA completes inspection o

United States Food and Drug Administration (USFDA) has completed inspection carried out at Lupin’s Nagpur oral solid manufacturing facility. The inspection was carried out between August 5, 2019 and August 8, 2019. The inspection for the oral solid facility at Nagpur closed without any 483 observations.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

United States Food and Drug Administration (USFDA) has complete..
06Aug08-06-2019$ANSM completes inspection at Lupin’s Mandideep facility ANSM completes inspection at

The French National Agency for Medicines and Health Products Safety (ANSM) has completed the Good Manufacturing Practices (GMP) inspection at Lupin’s finished product manufacturing facility (Unit-1) at Mandideep. The inspection was conducted between April 8, 2019 and April 12, 2019. The ANSM inspection closed with no critical or major observations.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

The French National Agency for Medicines and Health Products Sa..
Financials More
Rs. in Millions
QTR Jun 19 ANNUAL 19
Net Profit4459.315388.3
Gross Profit 6087.7 23423.7
Operating Profit 7484.931441.2
Net Sales 29408113563.2
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Astrazeneca Pharma I (BSE)
 1708.40 (1.53%)
M.Cap ( in Cr)
4271.00
Everest Organics (BSE)
 172.65 (17.45%)
M.Cap ( in Cr)
138.12
Piramal Enterprises (BSE)
 1782.55 (0.90%)
M.Cap ( in Cr)
35445.39
Ajanta Pharma (BSE)
 996.45 (1.56%)
M.Cap ( in Cr)
8694.50
Samrat Pharmachem (BSE)
 73.20 (20.00%)
M.Cap ( in Cr)
22.62
Shareholding Pattern More
MUTUAL FUNDS/UTI 7.08 %
FI/BANKS/INSURANCE 5.95 %
PROMOTERS 46.96 %
NON-INSTITUTION 14.38 %
GOVERNMENT 0.28 %
FII 0 %
F & O Quotes